(Q46394413)

21 December 2017

title

Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase (English)

1 reference

21 December 2017

0 references

3

Ulrike Kuckelkorn

1 reference

21 December 2017

author name string

Ivana von Metzler

1

1 reference

21 December 2017

Holger Krebbel

2

1 reference

21 December 2017

Ulrike Heider

4

1 reference

21 December 2017

Christian Jakob

5

1 reference

21 December 2017

Martin Kaiser

6

1 reference

21 December 2017

Claudia Fleissner

7

1 reference

21 December 2017

Evangelos Terpos

8

1 reference

21 December 2017

Orhan Sezer

9

1 reference

21 December 2017

publication date

3 September 2008

1 reference

21 December 2017

Journal of Cancer Research and Clinical Oncology

published in

1 reference

21 December 2017

volume

135

1 reference

21 December 2017

issue

2

1 reference

21 December 2017

page(s)

173-179

1 reference

21 December 2017

Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-008-0461-8

Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-008-0461-8

Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-008-0461-8

Evidence for the secretion of an osteoclast stimulating factor in myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-008-0461-8

Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.

21 January 2018

1 reference

12 December 2020

Bone markers in multiple myeloma

1 reference

12 December 2020

Myeloma bone disease and proteasome inhibition therapies.

1 reference

12 December 2020

A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits

1 reference

12 December 2020

Osteoclast differentiation and activation

1 reference

12 December 2020

Proteasome: an emerging target for cancer therapy

1 reference

12 December 2020

Comparison of human COP9 signalsome and 26S proteasome lid'.

1 reference

12 December 2020

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

1 reference

12 December 2020

The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

1 reference

12 December 2020

I kappa B: a specific inhibitor of the NF-kappa B transcription factor

1 reference

12 December 2020

Proteasome as an emerging therapeutic target in cancer

1 reference

12 December 2020

Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway.

1 reference

12 December 2020

Parathyroid hormone (PTH)-related protein is a potent stimulator of osteoclast-like multinucleated cell formation to the same extent as PTH in mouse marrow cultures.

1 reference

12 December 2020

A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function

1 reference

12 December 2020

Prostaglandin-mediated hypercalcemia: A paraneoplastic syndrome

1 reference

12 December 2020

Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo

1 reference

12 December 2020

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

1 reference

12 December 2020

Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uP

1 reference

12 December 2020

Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries.

1 reference

12 December 2020

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

1 reference

12 December 2020

Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo

1 reference

12 December 2020

Skeletal disease resulting from disturbed endocrine function or from errors in metabolism

1 reference

12 December 2020

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

1 reference

12 December 2020

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis

1 reference

12 December 2020

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

12 December 2020

Direct action of the parathyroid hormone-like human hypercalcemic factor on bone

1 reference

12 December 2020

Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells

1 reference

12 December 2020

RANK ligand and osteoprotegerin in myeloma bone disease.

1 reference

12 December 2020

Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

1 reference

12 December 2020

The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated

1 reference

12 December 2020

Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.

1 reference

12 December 2020

The IKK NF-kappa B system: a treasure trove for drug development

1 reference

12 December 2020

Bortezomib inhibits human osteoclastogenesis.

1 reference

12 December 2020

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases

1 reference

12 December 2020

Bacterially induced bone destruction: mechanisms and misconceptions.

1 reference

12 December 2020

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

1 reference

12 December 2020

Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL.

1 reference

12 December 2020

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology

1 reference

12 December 2020

10.1007/S00432-008-0461-8

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017